STD AAPPS FOA Frequently Asked Questions
This web page is archived for historical purposes and is no longer being updated.
1. The FOA mentions public/private partnerships; can you list some examples?
Examples are included in the Project Description/Approach/Program Strategy section of the FOA:
- Health Resources Services Administration (HRSA) programs such as Ryan White HIV/AIDS programs; federally qualified health centers; and state maternal and child health programs.
- Programs funded by the HHS Office of Population Affairs and Office of Adolescent Health, such as family planning clinics and teen pregnancy prevention programs, and their state Medicaid program.
- Other organizations may include: 1) health plans; 2) state primary care associations; 3) professional medical and nursing organizations; 4) state and local education agencies; 5) organizations providing services to incarcerated populations; and 6) schools of public health and other academic institutions.
- Innovative partnerships with the business community or others are also encouraged.
(July 9, 2013)
2. What appropriate and evidence-based interventions are available to reduce reinfections among high-risk clients?
DSTDP recognizes the need to build upon the evidence base for STD interventions and is in the planning process for how to do so.
We are compiling existing evidence for a variety of interventions and have developed a resource that is available on the FOA resource webpage.
This resource will be updated as additional evidence becomes available. (July 9, 2013)
3. How do I know if my project area meets the CDC definition of high morbidity for congenital syphilis?
Applicants should treat any number of cases greater than zero as a high number of congenital syphilis cases.
Congenital syphilis is a serious but rare disease, with fewer than 500 cases reported nationwide for each of the last 10 years (range of 339 – 460 cases).
In 2011, only 23 states reported any cases. (July 9, 2013)
4. What constitutes a ‘large health plan,’ as listed in the Assessment/Monitor Screening Rates section of the FOA?
A large health plan is a plan that has a significant share of the health insurance market in a given geographic area. (July 9, 2013)
5. What percentage of 15-24 year-olds are sexually active?
Given the differences in sexual activity between 15-19 and 20-24 year olds, CDC typically publishes data from national surveys separately for these age groups.
The most recent data on sexual activity for these age groups is from the 2006-2008 National Survey of Family Growth.
Consistent with CDC STD screening recommendations, CDC defines sexually active as ‘sex in the past 12 months.’
Using data from Sexual Behavior, Sexual Attraction, and Sexual Identity in the United States: Data From the 2006–2008 National Survey of Family Growth, the percentages of sexually active adolescents and young adults are estimated as follows:
- Females 15-19 years of age: 48.7%
- Females 20-24 years of age: 84.2%
- Males 15-19 years of age: 51.1%
- Males 20-24 years of age: 81.7%
(July 9, 2013)
6. Will CDC provide a Word version of the FOA?
No, CDC will not provide a Word version of the FOA. (July 11, 2013)
7. Will awardees be required to submit an interim report each year for STD AAPPS?
No, interim reports are not required.
Awardees must submit one annual report per year.
More information can be found in the ‘Reporting’ section of the FOA. If progress towards outputs and outcomes is not being made then additional reports may be required by CDC. (July 11, 2013)
8. The FOA states that awardees will only be required to submit an Annual Performance Report, but also state that the Report is due 120 days (4 months) before the end of the budget period. With this timeline, awardees will only be able to report on 8 months of data. Is this correct? Is it expected that the Annual Performance Report will be submitted with future grant applications?
The annual performance report will serve as the continuation application.
The Annual Performance Report is due 120 days prior to the end of the budget period in order for CDC to process the continuation applications in time for the next budget period.
The data to report and the time period to include in this report has not yet been established.
This will be determined during the first year of the project and the process is intended to be collaborative with funded project areas and NCSD. It will be part of the evaluation and performance measure plan process as described under the Evaluation and Performance Measure Plan FAQs. (July 11, 2013)
9. Please define STD Clinic.
A clinic or clinical setting where quality STD services are provided. (August 1, 2013)
10. Is it recommended that project areas partner with other federally funded prevention programs “to develop integrated prevention packages for primary care?” Please define “prevention packages.”
Yes, CDC recommends local and state STD programs partner with other federally funded programs, such as local and state HIV and hepatitis prevention programs, to develop prevention packages for integration into primary care. Prevention packages are any combination of services (e.g. screening and treatment services, health education materials, and partner services) across programs (e.g., STD, HIV, and Hepatitis) that address the needs of our at-risk populations (e.g., MSM) seeking services at key primary care providers. (August 5, 2013)
11. In the Gonococcal Isolate Surveillance Project (GISP) portions of the FOA, there are several references to the “local public health laboratory.” Are applicants required to utilize the health department laboratory for processing GISP specimens? If a relationship with another reputable lab exists, is it acceptable to utilize this site for the GISP application?
An appropriate clinical site can use another laboratory (besides a local public health laboratory) if the other laboratory is proficient at performing culture for N. gonorrhoeae, proficient at handling, storing, and shipping N. gonorrhoeae, supports participating in GISP, is able to handle the volume of culture specimens generated by participation in GISP, is willing to work closely with the clinical site to properly assign GISP identification numbers and monitor progress, is willing to ship isolates to the appropriate reference laboratory monthly, and follow the GISP protocol. (August 7, 2013)
12. Will the scoring of project area applications impact their funding allocation?
Scoring of project area applications will not impact funding allocation for year one. CDC is considering options to reward and incentivize innovation and quality in future years. Additionally, all project areas should keep in mind that CDC reserves the right to take action if grantees are not meeting expectations, which may include funding-related actions. Funding amounts are dependent on the availability of funds. (August 7, 2013)
13. Where will the awardee meeting for Part A- STD AAPPS and Part B- GISP be located? If staffing for Part A and Part B in the application will be the same, can we budget for this travel under Part A but not under Part B?
CDC will advise where the awardee meeting will be held when information becomes available. Should applicants receive funding for Parts A&B and staffing for both parts is shared, it is acceptable to budget for this travel under Part A only. (August 21, 2013)